SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is experiencing extreme volatility and intense debate as investors weigh the impact of upcoming insider lock-up expirations against the company's long-term AI and aerospace infrastructure ambitions. The community remains sharply divided between short sellers betting on further downside and bulls who view the recent sell-off as a prime entry point for a sector leader.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing intense volatility and a sharp downward slide as part of a broader rout in the semiconductor and memory sectors, fueled by concerns over Chinese competition and heavy institutional profit-taking. The community is sharply divided between "bottom fishers" looking to capitalize on perceived oversold levels before upcoming earnings and skeptical traders who view the recent parabolic rally as a bubble that has finally burst.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Singapore.

Seagate Technology Holdings Plc

Seagate is experiencing heightened volatility and intense community scrutiny as investors weigh its role in the AI storage bottleneck against recent technical pullbacks and institutional settlement news. Market participants are actively debating whether the stock's recent price action represents a healthy consolidation within a long-term AI-driven growth cycle or a deeper structural reset for the data storage sector.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently capturing significant market attention following a stellar earnings report that highlighted accelerating AI demand, record operating margins, and increased guidance. Investors are actively debating the company's valuation against its massive year-over-year revenue growth, with community sentiment largely focused on its crucial role in the AI server infrastructure supply chain.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently rallying as investors rotate back into AI infrastructure plays, supported by recent analyst upgrades that highlight its strategic role in meeting massive data center power demand. While the stock continues to experience high volatility, market participants are actively debating the impact of ongoing institutional call buying against concerns over supply chain transparency and sector-wide macro headwinds.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending due to a significant regulatory pivot, as the company secured an agreement with the FDA to resubmit its BLA for RP1 in advanced melanoma, sparking investor optimism regarding the potential for approval after two prior rejections. The community is actively debating the reliability of this path forward, with discussions centered on potential political influence versus scientific merit, concerns about the company's financial stability, and high levels of short interest driving intense volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors debate the potential for upcoming global expansion announcements following recent comments from leadership, while the community remains divided over the stock's significant short interest and the lack of immediate catalysts. Long-term shareholders are focusing on the company's clinical pipeline and potential for institutional partnerships, even as persistent price volatility fuels intense speculation and frustration within the retail base.

JetBlue Airways Corp. engages in the provision of air transportation services. Its brands include jetBlue, jetBlue Vacations, Paisly, and TrueBlue. It operates through the following geographic segments: Domestic and Canada, Caribbean and Latin America, and Atlantic. The company was founded by David Gary Neeleman in August 1998 and is headquartered in Long Island City, NY.

Jetblue Airways Corp

JetBlue is experiencing heightened volatility and trader attention following the collapse of Spirit Airlines, which has prompted aggressive market share expansion efforts and speculation regarding potential industry consolidation. While investors are debating whether the airline can successfully absorb new routes and capitalize on reduced competition, concerns persist regarding its significant debt burden and susceptibility to ongoing fuel price volatility.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is trending as investors rotate into defensive, high-conviction large-cap stocks following a strong earnings beat and raised full-year guidance. The community is actively discussing the stock's resilience against broader market volatility and its position as a reliable alternative to cooling tech-sector momentum.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid intense investor debate over the escalating geopolitical conflict in the Middle East and its impact on global energy supplies. While some traders are betting on further upside due to potential supply disruptions in the Strait of Hormuz, others are focused on volatility triggered by diplomatic headlines and official statements regarding potential ceasefire efforts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward

Equity

Alliance Global said that the upcoming FDA advisory committee meeting now appears to be an ‘uphill battle’ for Capricor.


Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Capricor Therapeutics, Inc. (Capricor or the Company) (NASDAQ: CAPR) investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CAPRICOR THERAPEUTICS, INC...

Nasdaq, S&P 500 Futures Slip As Korea Chip Shock Dents AI Memory Heavyweights Ahead Of Fed Decision: Why NVDA, SNDK, MU, APLD, SPCX, SLS, CAPR Are In Focus

Retail sentiment remains ‘bearish’ on SPY and deteriorated to ‘extremely bearish’ on QQQ, amid growing anxiety around technology stocks.


CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts — ‘Pharma Bro’ Shkreli Piles On, But Retail Turns More Bullish Than Ever 

Wall Street turned more cautious, with Roth, B. Riley and Cantor flagging elevated approval risk.

US Stock Futures Retreat Amid Chip Pressure Even As Oil Pulls Back On Iran Optimism: APLD, CAPR, NVDA, AMKR In Focus

Markets are largely focused on pivotal earnings from major hyperscalers this week, including Amazon.com, Apple, Meta and Microsoft. 

Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation CAPR

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially misleading business information to the...

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (Capricor or the Company) (NASDAQ: CAPR) on behalf of investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CAPRICOR THERAPEUTICS, INC...

CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ 

The documents released by the FDA on Monday, ahead of an advisory committee meeting to review Capricor’s application for Deramiocel, have raised a divide among Wall Street experts over what to expect.


Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data

FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July 29.read more...

QUICK SPARK: Capricor Stock Dives  'Complete Fraud' Says Pharma Bro Martin Shkreli

Martin Shkreli accuses Capricor Therapeutics of fraud and predicts legal action against its CEO and consultant over patient data.read more...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Extremely Bullish Sentiment

$SNDK

$STX

$SKHY

Memory stocks have been one of the market's most volatile trades this year and are down sharply in recent weeks. Which are you most interested in buying or adding to on this pullback? Vote and explain your reasoning in the comments.

Which memory stock are you most tempted to buy on the pullback: $MU, $SNDK, $STX, or $SKHY? 
 
Drop a comment if you prefer $DRAM or another memory play.

Stocktwits

Micron Technology Inc

SK Hynix Inc - ADR

Roundhill ETF Trust - Roundhill Memory ETF

Which memory stock are you most tempted to buy on the pullback: 

Stocktwits Polls

Investors are closely watching the high-stakes Advisory Committee meeting to determine the future of deramiocel amid intense regulatory scrutiny.

A core debate rages over whether the company used the correct statistical analysis plan or improperly altered trial data mid-study.

Growing skepticism regarding the agency's recent transparency, with reports of removed briefing documents and questionable internal procedures.

Bullish traders are bracing for significant volatility, anticipating that a positive AdCom result could trigger a violent move to the upside.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.59	--	--	N/A
Q1 '26	-$0.51	-$0.59	-16.26%	MISSED
Q4 '25	-$0.51	-$0.62	-21.81%	MISSED
Q3 '25	-$0.55	-$0.54	1.22%	BEAT
Q2 '25	-$0.48	-$0.57	-19.75%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

CAPRCapricor Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest CAPR News